Ultrashape System in Combination With VelaShape II Device for Circumferential Reduction

Inclusion Criteria: 1. Fat thickness of at least 1.5 cm in the anterior abdominal and flanks prior to initial treatment (measurement by caliper) 2. For women of child-bearing potential: negative pregnancy test in the 24 hour period prior to enrollment and 24 hour period prior to each treatment or FU visit (measured in urine) 3. General good health confirmed by medical history and skin examination of the treated area 4. Written informed consent to participate in the study 5. Ability to comply with the requirements of the study 6. BMI≤ 30 Exclusion Criteria: 1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism 2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease or malignancy 3. Previous liposuction in the treatment areas 4. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing 5. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area 6. Poor skin quality (i.e., laxity) 7. Abdominal wall diastasis or hernia on physical examination 8. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months 9. Obesity (BMI \> 30) 10. Childbirth within the last 12 months or women who suckling a child 11. Any acute or chronic condition which, in the opinion of the Investigator, could interfere with the conduct of the study 12. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months) 13. Inability to comply with circumference measurement procedure (e.g., inability to held breath for the required duration) 14. Participation in another clinical study 15. Previous body contouring treatments in the treatment areas